Okeiro

Executive Summary

Okeiro is a French digital health company pioneering a precision medicine platform for transplant recipients and patients with chronic organ insufficiencies. Founded in 2019 and headquartered in Paris, the company leverages multidimensional patient data and validated predictive algorithms to enable remote monitoring, forecast clinical outcomes, and personalize interventions. By bridging clinical care with research, Okeiro aims to accelerate therapeutic innovation while improving patient management and quality of life. Its platform addresses critical gaps in post-transplant care and chronic disease management, where timely interventions can prevent complications and reduce hospitalizations. As a private company with no disclosed funding, Okeiro operates in the competitive digital health and diagnostics space, with potential to disrupt traditional reactive care models through proactive, data-driven insights. The company's focus on transplant recipients—a highly vulnerable population—underscores its niche value proposition. Okeiro's algorithms analyze complex physiological and clinical data to predict adverse events such as rejection or infection, enabling clinicians to act early. This approach not only improves patient outcomes but also reduces healthcare costs. While still early-stage, Okeiro's platform has the potential to become a standard tool in transplant centers and chronic disease clinics. Given the growing demand for remote monitoring solutions and the increasing adoption of AI in healthcare, Okeiro is well-positioned for growth. However, the company faces challenges in regulatory clearance, clinical validation, and commercialization. If successful, Okeiro could transform how organ insufficiency is managed, shifting from episodic care to continuous, personalized surveillance.

Upcoming Catalysts (preview)

• Q3 2026First CE Mark Certification for Predictive Algorithms65% success
• Q4 2026Partnership with Major French Hospital Network50% success
• Q1 2027Publication of Real-World Evidence Study in Transplant Patients70% success